Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: RVMD stock price vs MMI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MMI's multiple
Needs MMI P/S.
Implied fair value · at RVMD's multiple
Needs RVMD P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVMD FY 2023 (ended Dec 31, 2023) · MMI FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Revolution Medicines, Inc. · implied price per share
Bear
$5.37
Base
$6.32
Bull
$7.27
MARCUS & MILLICHAP, INC. · implied price per share
Bear
-$3.12
Base
-$3.66
Bull
-$4.21
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.39x
0.27x
Net debt / EBITDA
Leverage against operating earnings
1.24x
-4.38x
Cash and equivalents
Liquid reserves on the balance sheet
$2.03B
$235.87M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
CBRE GROUP, INC.
RVMD vs CBRE
JONES LANG LASALLE INC
RVMD vs JLL
Compass, Inc.
RVMD vs COMP
AZEK Co Inc.
RVMD vs AZEK
$642.17M
$163.64M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
